Reminds me of Curis (CRIS) GDC-0449 with what they were able to achieve in their 50 person trial in Basal Cell Carcinoma. (Take a look at the NEJM article and pictures - QUITE amazing). -CRIS problem now is their drug has been pathetic in 2 major indications NOT driven by the hedgehog mutation.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.